Symbols / SCNX Stock $0.41 -1.87% Scienture Holdings, Inc.

Healthcare • Pharmaceutical Retailers • United States • NCM
SCNX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Pharmaceutical Retailers
CEO Dr. Shankar Hariharan Ph.D.
Exch · Country NCM · United States
Market Cap 16.67M
Enterprise Value 10.03M
Income -41.51M
Sales 431.61K
FCF (ttm) -362.07K
Book/sh 1.73
Cash/sh 0.16
Employees 4
Insider 10d —
IPO Feb 06, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.32
Forward P/E -1.95
PEG —
P/S 38.62
P/B 0.24
P/C —
EV/EBITDA -0.64
EV/Sales 23.24
Quick Ratio 2.70
Current Ratio 2.89
Debt/Eq 0.03
LT Debt/Eq —
EPS (ttm) -2.70
EPS next Y -0.21
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-30
Earnings (prior) 2026-03-30
ROA -10.74%
ROE -55.65%
ROIC —
Gross Margin 76.80%
Oper. Margin 18.70%
Profit Margin 0.00%
Shs Outstand 40.63M
Shs Float 32.79M
Insider Own 21.88%
Instit Own 3.72%
Short Float 5.10%
Short Ratio 1.94
Short Interest 1.72M
52W High 2.60
vs 52W High -84.22%
52W Low 0.24
vs 52W Low 72.35%
Beta —
Impl. Vol. —
Rel Volume 0.11
Avg Volume 3.08M
Volume 326.40K
Target (mean) $1.50
Tgt Median $1.50
Tgt Low $1.50
Tgt High $1.50
# Analysts 1
Recom None
Prev Close $0.42
Price $0.41
Change -1.87%
About

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.50
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-0.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
$1.50
High
$1.50
Mean
$1.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-24 init Maxim Group — → Buy $2
News
RSS: Latest SCNX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-20 NARASIMHAN MANI Chief Executive Officer — 1,550,000 $0.00 $0
2026-02-20 HARIHARAN SHANKAR PH.D. Chief Executive Officer — 1,550,000 $0.00 $0
2024-09-19 NARASIMHAN MANI Chief Executive Officer — 1,357,538 — —
2024-09-19 HARIHARAN SHANKAR PH.D. Chief Executive Officer — 2,273,296 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.43
+215.87%
0.14
-89.98%
1.36
-86.69%
10.25
Operating Revenue
0.43
+215.87%
0.14
-89.98%
1.36
-86.69%
10.25
Cost Of Revenue
0.10
-23.36%
0.13
-90.06%
1.31
-72.21%
4.73
Reconciled Cost Of Revenue
0.10
-23.36%
0.13
-90.06%
1.31
-72.21%
4.73
Gross Profit
0.33
+5420.10%
0.01
-87.75%
0.05
-99.11%
5.52
Operating Expense
16.58
+12.71%
14.71
+230.83%
4.45
-41.20%
7.56
Research And Development
1.96
-12.54%
2.24
0.00
-100.00%
0.99
Selling General And Administration
14.52
+20.48%
12.05
+177.41%
4.35
-33.83%
6.57
General And Administrative Expense
14.52
+20.48%
12.05
+177.41%
4.35
-33.83%
6.57
Salaries And Wages
2.12
+0.36%
2.11
+236.94%
0.63
-82.50%
3.58
Other Gand A
12.40
+24.75%
9.94
+167.38%
3.72
+24.55%
2.99
Other Operating Expenses
0.10
-76.64%
0.42
+315.15%
0.10
-89.90%
0.99
Total Expenses
16.68
+12.39%
14.84
+157.59%
5.76
-53.13%
12.29
Operating Income
-16.24
-10.50%
-14.70
-234.38%
-4.40
-115.44%
-2.04
Total Operating Income As Reported
-42.59
-189.71%
-14.70
-234.38%
-4.40
-50.77%
-2.92
EBITDA
-38.93
-123.88%
-17.39
-176.48%
-6.29
-235.90%
-1.87
Normalized EBITDA
-15.50
-6.83%
-14.51
-334.19%
-3.34
-83.14%
-1.83
Reconciled Depreciation
0.49
+821.61%
0.05
-94.92%
1.05
+439.19%
0.19
EBIT
-39.42
-126.01%
-17.44
-137.66%
-7.34
-255.05%
-2.07
Total Unusual Items
-23.43
-714.17%
-2.88
+2.37%
-2.95
-6104.24%
-0.05
Total Unusual Items Excluding Goodwill
-23.43
-714.17%
-2.88
+2.37%
-2.95
-6104.24%
-0.05
Special Income Charges
-26.63
-826.42%
-2.87
-2.72%
-2.80
-220.60%
-0.87
Impairment Of Capital Assets
26.35
—
5.13
0.00
Write Off
0.00
-100.00%
2.50
0.00
-100.00%
0.88
Net Income
-41.51
-557.90%
9.07
+150.81%
-17.84
-413.91%
-3.47
Pretax Income
-43.51
-131.68%
-18.78
-121.37%
-8.48
-252.95%
-2.40
Net Non Operating Interest Income Expense
-3.78
-214.96%
-1.20
-5.38%
-1.14
-261.35%
-0.32
Interest Expense Non Operating
4.08
+205.71%
1.34
+16.83%
1.14
+240.04%
0.34
Net Interest Income
-3.78
-214.96%
-1.20
-5.38%
-1.14
-261.35%
-0.32
Interest Expense
4.08
+205.71%
1.34
+16.83%
1.14
+240.04%
0.34
Interest Income Non Operating
0.30
+123.67%
0.14
+3123.84%
0.00
-80.00%
0.02
Interest Income
0.30
+123.67%
0.14
+3123.84%
0.00
-80.00%
0.02
Other Income Expense
-23.48
-716.03%
-2.88
+2.37%
-2.95
-6104.24%
-0.05
Other Non Operating Income Expenses
-0.05
—
0.01
—
Gain On Sale Of Security
3.21
+123449.52%
-0.00
+98.25%
-0.15
-117.98%
0.83
Gain On Sale Of Business
-0.29
0.00
—
—
Tax Provision
-1.99
-273.30%
-0.53
0.00
—
Tax Rate For Calcs
0.00
+61.13%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-1.07
-1211.84%
-0.08
0.00
0.00
Net Income Including Noncontrolling Interests
-41.51
-557.90%
9.07
+150.81%
-17.84
-356.37%
-3.91
Net Income From Continuing Operation Net Minority Interest
-41.51
-127.53%
-18.24
-115.07%
-8.48
-331.55%
-1.97
Net Income From Continuing And Discontinued Operation
-41.51
-557.90%
9.07
+150.81%
-17.84
-413.91%
-3.47
Net Income Continuous Operations
-41.51
-127.53%
-18.24
-115.07%
-8.48
-252.95%
-2.40
Net Income Discontinuous Operations
0.00
-100.00%
27.31
+391.75%
-9.36
-521.39%
-1.51
Minority Interests
—
—
0.00
-100.00%
0.44
Normalized Income
-19.16
-24.01%
-15.45
-179.09%
-5.54
-188.58%
-1.92
Net Income Common Stockholders
-41.51
-557.90%
9.07
+150.81%
-17.84
-413.91%
-3.47
Diluted EPS
-2.70
-208.87%
2.48
+110.62%
-23.35
-279.67%
-6.15
Basic EPS
-2.70
-200.37%
2.69
+111.52%
-23.35
-279.67%
-6.15
Basic Average Shares
15.35
+354.69%
3.38
+341.76%
0.76
+35.26%
0.56
Diluted Average Shares
15.35
+320.06%
3.65
+53.42%
2.38
+321.60%
0.56
Diluted NI Availto Com Stockholders
-41.51
-557.90%
9.07
+150.81%
-17.84
-413.91%
-3.47
Gain On Sale Of PPE
0.00
+100.00%
-0.37
+86.60%
-2.80
-127325.82%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
84.18
-19.72%
104.85
+736.63%
12.53
+237.81%
3.71
Current Assets
7.92
+25.55%
6.31
+129.03%
2.75
+31.53%
2.09
Cash Cash Equivalents And Short Term Investments
6.66
+2062.32%
0.31
+98019.75%
0.00
-99.97%
1.09
Cash And Cash Equivalents
6.66
+2062.32%
0.31
+98019.75%
0.00
-99.97%
1.09
Cash Financial
6.66
+2062.32%
0.31
+98019.75%
0.00
-99.97%
1.09
Receivables
0.73
-86.58%
5.45
+115.86%
2.52
+300.80%
0.63
Accounts Receivable
0.73
+6484.98%
0.01
0.00
-100.00%
0.63
Gross Accounts Receivable
—
—
0.85
+17.17%
0.73
Allowance For Doubtful Accounts Receivable
—
—
-0.03
+67.55%
-0.10
Other Receivables
—
4.14
+237.94%
1.22
—
Inventory
0.21
0.00
-100.00%
0.00
-98.52%
0.07
Raw Materials
—
—
0.00
-100.00%
0.07
Finished Goods
0.21
0.00
-100.00%
0.00
0.00
Prepaid Assets
0.26
+5651.71%
0.00
-91.01%
0.05
-51.44%
0.10
Current Deferred Assets
0.05
-91.14%
0.53
0.00
—
Assets Held For Sale Current
0.00
-100.00%
0.01
-95.38%
0.18
-11.08%
0.20
Total Non Current Assets
76.26
-22.61%
98.55
+907.67%
9.78
+504.85%
1.62
Net PPE
0.04
-82.25%
0.22
+10.17%
0.20
-82.21%
1.12
Gross PPE
0.04
-82.25%
0.22
+10.17%
0.20
-82.21%
1.12
Other Properties
0.04
-82.25%
0.22
+10.17%
0.20
-82.21%
1.12
Goodwill And Other Intangible Assets
70.97
-27.41%
97.77
0.00
0.00
Goodwill
0.00
-100.00%
21.37
0.00
—
Other Intangible Assets
70.97
-7.10%
76.40
+752.42%
8.96
—
Non Current Accounts Receivable
0.25
—
—
—
Non Current Deferred Assets
0.00
-100.00%
0.53
—
—
Non Current Deferred Taxes Assets
0.00
-100.00%
0.53
—
—
Non Current Prepaid Assets
0.00
-100.00%
0.02
+109.28%
0.01
-78.52%
0.05
Other Non Current Assets
—
—
9.57
+2022.81%
0.45
Total Liabilities Net Minority Interest
14.06
-45.47%
25.78
+115.02%
11.99
+256.10%
3.37
Current Liabilities
2.74
-65.41%
7.91
-31.58%
11.56
+438.31%
2.15
Payables And Accrued Expenses
2.10
-50.14%
4.21
+159.51%
1.62
+88.40%
0.86
Payables
1.44
-50.21%
2.90
+98.13%
1.46
+147.81%
0.59
Accounts Payable
1.44
-50.21%
2.90
+98.13%
1.46
+177.09%
0.53
Other Payable
—
—
0.42
+573.68%
0.06
Current Accrued Expenses
0.66
-49.99%
1.31
+719.99%
0.16
-40.93%
0.27
Current Debt And Capital Lease Obligation
0.02
-99.13%
2.76
+8379.08%
0.03
-91.03%
0.36
Current Debt
—
2.70
-58.65%
6.53
+3817.99%
0.17
Other Current Borrowings
—
2.70
-58.65%
6.53
+3817.99%
0.17
Current Capital Lease Obligation
0.02
-61.89%
0.06
+94.31%
0.03
-83.44%
0.20
Current Deferred Liabilities
—
—
0.00
-100.00%
0.01
Current Deferred Revenue
—
—
0.00
-100.00%
0.01
Other Current Liabilities
0.61
-34.36%
0.93
-90.60%
9.90
+980.23%
0.92
Total Non Current Liabilities Net Minority Interest
11.32
-36.66%
17.87
+4016.67%
0.43
-64.42%
1.22
Liabilities Heldfor Sale Non Current
—
0.00
-100.00%
0.26
—
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.77
+334.54%
0.18
-85.50%
1.22
Long Term Debt
—
0.61
+2349.10%
0.03
-92.50%
0.33
Long Term Capital Lease Obligation
0.00
-100.00%
0.16
-11.55%
0.18
-80.06%
0.89
Non Current Deferred Liabilities
11.04
-18.39%
13.52
—
—
Non Current Deferred Taxes Liabilities
11.04
-18.39%
13.52
—
—
Other Non Current Liabilities
0.28
-77.82%
1.28
—
—
Stockholders Equity
70.12
-11.32%
79.07
+14479.46%
0.54
-28.93%
0.76
Common Stock Equity
70.12
-11.32%
79.07
+14479.46%
0.54
-28.93%
0.76
Capital Stock
0.00
+366.67%
0.00
+866.67%
0.00
+50.00%
0.00
Common Stock
0.00
+366.67%
0.00
+866.67%
0.00
+50.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
40.63
+364.32%
8.75
+866.91%
0.91
+44.51%
0.63
Ordinary Shares Number
40.63
+364.32%
8.75
+866.91%
0.91
+44.51%
0.63
Additional Paid In Capital
150.67
+27.57%
118.11
+249.56%
33.79
+64.96%
20.48
Retained Earnings
-80.55
-106.34%
-39.04
-17.42%
-33.25
-68.59%
-19.72
Minority Interest
—
—
0.00
+100.00%
-0.42
Total Equity Gross Minority Interest
70.12
-11.32%
79.07
+14479.46%
0.54
+58.18%
0.34
Total Capitalization
70.12
-12.00%
79.68
+14592.35%
0.54
-50.54%
1.10
Working Capital
5.18
+423.53%
-1.60
+81.81%
-8.80
-16303.24%
-0.05
Invested Capital
70.12
-14.89%
82.38
+15090.26%
0.54
-57.06%
1.26
Total Debt
0.02
-99.32%
3.53
+1586.13%
0.21
-86.77%
1.58
Net Debt
—
3.00
-53.08%
6.40
—
Capital Lease Obligations
0.02
-89.02%
0.22
+4.92%
0.21
-80.67%
1.08
Net Tangible Assets
-0.85
+95.44%
-18.70
-3548.09%
0.54
-28.93%
0.76
Tangible Book Value
-0.85
+95.44%
-18.70
-3548.09%
0.54
-28.93%
0.76
Current Notes Payable
—
—
—
0.17
Derivative Product Liabilities
0.00
-100.00%
2.30
0.00
—
Non Current Note Receivables
5.00
0.00
—
—
Notes Receivable
0.00
-100.00%
1.30
+0.00%
1.30
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.38
+6.21%
-14.27
-541.08%
-2.23
-42.21%
-1.56
Cash Flow From Continuing Operating Activities
-13.38
-0.72%
-13.29
-464.48%
3.65
+1931.60%
-0.20
Cash From Discontinued Operating Activities
0.00
+100.29%
-0.98
+83.32%
-5.87
-329.87%
-1.37
Net Income From Continuing Operations
-43.51
-131.68%
-18.78
-121.37%
-8.48
-252.95%
-2.40
Depreciation Amortization Depletion
0.49
+821.61%
0.05
-94.92%
1.05
+439.19%
0.19
Depreciation
0.04
-28.91%
0.05
-77.30%
0.24
+20.72%
0.19
Amortization Cash Flow
0.45
0.00
-100.00%
0.81
0.00
Depreciation And Amortization
0.49
+821.61%
0.05
-94.92%
1.05
+439.19%
0.19
Amortization Of Intangibles
0.45
0.00
-100.00%
0.81
0.00
Other Non Cash Items
7.27
+32.01%
5.51
+2037.84%
0.26
+1.44%
0.25
Stock Based Compensation
2.07
+7986.66%
0.03
-90.07%
0.26
+1.44%
0.25
Asset Impairment Charge
26.35
+953.84%
2.50
-51.26%
5.13
+260.93%
1.42
Operating Gains Losses
-2.99
-115196.88%
0.00
-98.54%
0.18
+131.49%
0.08
Gain Loss On Investment Securities
-3.21
-123449.52%
0.00
-98.54%
0.18
+125.05%
0.08
Change In Working Capital
-3.07
-17.92%
-2.60
-147.15%
5.51
+2040.39%
0.26
Change In Receivables
-0.80
+72.63%
-2.93
-433.10%
-0.55
-8.59%
-0.51
Changes In Account Receivables
-0.72
-6384.98%
-0.01
+96.22%
-0.29
-179.42%
0.37
Change In Inventory
-0.21
-22146.28%
0.00
-99.98%
4.23
+8281.66%
-0.05
Change In Prepaid Assets
-0.19
-656.97%
0.03
-9.67%
0.04
-88.55%
0.34
Change In Payables And Accrued Expense
-1.82
-549.50%
0.40
-79.97%
2.02
+17099.55%
-0.01
Change In Accrued Expense
-0.25
-457.14%
-0.04
-176.02%
0.06
+127.72%
-0.21
Change In Payable
-1.57
-449.38%
0.45
-77.09%
1.96
+879.63%
0.20
Change In Account Payable
-1.57
-449.38%
0.45
-72.10%
1.61
+704.48%
0.20
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
—
—
0.31
0.00
Change In Other Current Liabilities
-0.04
+62.78%
-0.11
+49.50%
-0.23
-145.92%
0.49
Investing Cash Flow
0.00
-100.00%
27.55
+10093.14%
-0.28
+35.56%
-0.43
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-2.38
-590.67%
-0.34
-46088.52%
0.00
Cash From Discontinued Investing Activities
0.00
-100.00%
29.93
+43445.42%
0.07
+116.04%
-0.43
Net PPE Purchase And Sale
0.00
+100.00%
-0.01
0.00
-100.00%
0.00
Purchase Of PPE
0.00
+100.00%
-0.01
—
0.00
Sale Of PPE
—
—
0.00
-100.00%
0.00
Capital Expenditure
—
-0.01
—
-0.45
Capital Expenditure Reported
—
—
0.00
0.00
Net Investment Purchase And Sale
0.00
+100.00%
-2.50
0.00
—
Purchase Of Investment
0.00
+100.00%
-2.50
0.00
—
Net Business Purchase And Sale
0.00
-100.00%
0.13
+138.60%
-0.34
0.00
Purchase Of Business
—
0.00
+100.00%
-0.34
0.00
Gain Loss On Sale Of Business
0.21
0.00
—
—
Net Other Investing Changes
—
-0.01
—
—
Financing Cash Flow
19.73
+252.03%
-12.98
-1022.95%
1.41
+4098.56%
-0.04
Cash Flow From Continuing Financing Activities
19.73
+252.09%
-12.97
-780.61%
1.91
+694.87%
0.24
Net Issuance Payments Of Debt
-6.16
-298.44%
3.10
+1141.60%
0.25
0.00
Issuance Of Debt
3.62
+16.49%
3.10
+676.00%
0.40
0.00
Repayment Of Debt
-9.78
0.00
+100.00%
-0.15
0.00
Long Term Debt Issuance
3.62
+16.49%
3.10
+676.00%
0.40
0.00
Long Term Debt Payments
-9.78
0.00
+100.00%
-0.15
0.00
Net Long Term Debt Issuance
-6.16
-298.44%
3.10
+1141.60%
0.25
0.00
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
26.29
0.00
0.00
-100.00%
0.13
Common Stock Dividend Paid
0.00
+100.00%
-14.86
0.00
—
Cash Dividends Paid
0.00
+100.00%
-14.86
0.00
—
Proceeds From Stock Option Exercised
0.00
-100.00%
0.03
+1528.05%
0.00
+85.37%
0.00
Net Other Financing Charges
-0.40
+67.91%
-1.25
-175.32%
1.65
+1431.63%
0.11
Changes In Cash
6.35
+1964.42%
0.31
+128.12%
-1.09
+46.02%
-2.03
Beginning Cash Position
0.31
+98019.75%
0.00
-99.97%
1.09
-64.94%
3.12
End Cash Position
6.66
+2062.32%
0.31
+98019.75%
0.00
-99.97%
1.09
Free Cash Flow
-13.38
+6.29%
-14.28
-541.62%
-2.23
-42.21%
-1.56
Interest Paid Supplemental Data
0.00
0.00
-100.00%
0.73
+118.23%
0.34
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Common Stock Issuance
26.29
0.00
0.00
-100.00%
0.13
Issuance Of Capital Stock
26.29
0.00
0.00
-100.00%
0.13
Sale Of Business
0.00
-100.00%
0.13
0.00
—
Cash From Discontinued Financing Activities
0.00
+100.00%
-0.01
+99.00%
-0.50
-81.82%
-0.28
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category